# A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.

> **NCT07190716** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Single Ascending Dose
- Healthy Subjects

## Interventions

- **BIOLOGICAL:** GR2301 injection

## Key facts

- **NCT ID:** NCT07190716
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2026-05-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190716, "A Study to Evaluate the Safety of GR2301 Injection in Healthy Volunteers.". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07190716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*